Triana Biomedicines: $120 Million Series B Secured To Advance Molecular Glue Degrader Pipeline
By Amit Chowdhry ● Dec 11, 2025
Triana Biomedicines has closed an oversubscribed $120 million Series B financing round that will accelerate development of its molecular glue degrader platform and advance its lead program, TRI-611, toward clinical proof-of-concept in patients with ALK-positive non-small cell lung cancer. The round was co-led by Ascenta Capital and Bessemer Venture Partners, with participation from new investors including YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures. Existing backers, including RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, and Surveyor Capital, also continued their support.